<DOC>
	<DOCNO>NCT01927718</DOCNO>
	<brief_summary>The goal clinical research study learn add low dose Thalidomide ( thalidomide ) Revlimid ( lenalidomide ) maintenance therapy help control MM autologous stem cell transplant . Researchers also want learn treatment study drug improve participant ' quality life .</brief_summary>
	<brief_title>Thalidomide Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation ( HCT )</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , begin take lenalidomide thalidomide mouth day , even . Thalidomide take least 1 hour even meal . Bedtime best time take thalidomide . Swallow lenalidomide thalidomide capsule whole least 4 ounce water . Do open , crush , break lenalidomide thalidomide capsule . If touch broken lenalidomide thalidomide capsule , wash affect area body soap water . If miss dose lenalidomide and/or thalidomide , le 12 hour since regular dosing time , take soon remember . If 12 hour , skip miss dose . Do take 2 dos time . If take much lenalidomide and/or thalidomide ( overdose ) , call primary healthcare provider poison control center right away . If vomit take dose , wait take another dose next scheduled time . You give patient study drug diary . You use diary write time take dose lenalidomide thalidomide . You need bring study drug diary every study visit study staff review . Since lenalidomide thalidomide increase risk develop blood clot , especially patient high risk history blood clot , may receive heparin , warfarin , aspirin help prevent blood clot . Your doctor decide medication need , doctor may decide need medication help prevent blood clot , base platelet count ( cell help blood clot ) . You give standard drug help decrease risk side effect . You may ask study staff information drug give risk . Study Visits : Once month first 6 month : - You physical exam . - You neurological exam ( test check function nerve , include test balance reflex ) . You ask numbness tingling may experience . - Blood ( 2 tablespoon ) urine collect routine test , liver kidney function test , blood clotting test ( need ) , test check status disease . If doctor think disease either go remission ( get good ) gotten bad , additional blood test bone marrow biopsy check status disease . After Month 6 , every even-numbered month study ( Months 8 , 10 , 12 , ) , blood ( 2 tablespoon ) urine collect routine test check status disease . Questionnaires : You ask complete questionnaire symptom quality life screening , month first 6 month , every month study . You sometimes fill questionnaire hand piece paper , may ask question telephone member study staff . Other time , questionnaire do phone automate phone system . The telephone system ask rate strong tolerable symptom , much symptom interfere daily life . Rating symptom use telephone system take less 5 minute call . The research nurse teach use automate telephone system . Length Treatment : You receive study drug 2 year . You longer able take study drug doctor think best interest , disease get bad , intolerable side effect occur , unable follow study direction keep appointment . Your participation study end-of-study visit . End-of-Study Visit : About 30 day last dose study drug : - You physical exam neurological exam . - Blood ( 2 tablespoon ) urine collect routine test check status disease . - You bone marrow biopsy check status disease , doctor think need . This investigational study . Lenalidomide Thalidomide FDA approve commercially available treatment myeloma . The use chemotherapy drug treat MM gotten bad treatment lenalidomide consider investigational . The study doctor explain study drug ( ) design work . Up 17 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Patient legally authorize representative able sign inform consent form . 2 . Age 18 year old old . 3 . Multiple myeloma show sign biochemical progression take lenalidomide lenalidomide plus dexamethasone maintenance therapy autologous hematopoietic stem cell transplantation . ( Progression define solely base serum urine Mprotein , patient without measurable serum urine Mprotein level ; difference involve uninvolved serum free light chain level please also see appendix E full detail . ) 4 . Patients biochemical progression least &gt; /= 25 % increase baseline follow parameter least 2 occasion ; treat physician deems change therapy necessary : a. Serum Mprotein ; b. Urine Mprotein ; , c. In patient without measureable serum urine Mprotein level ; difference involve uninvolved free light chain level . 5 . Lenalidomide must use least 6 month autologous hematopoietic stem cell transplantation current dose Lenalidomide 15 mg/day less . 6 . Serum creatinine clearance ( CockcroftGault Equation ) &gt; = 50 mL/minute . 7 . Performance score least 80 % Karnofsky 0 2 Eastern Cooperative Oncology Group ( ECOG ) . 8 . Patients must inform Celgene Risk Management Program mandatory registration well willing able comply requirement . 9 . Negative Beta Human Chorionic Gonadotropin ( HCG ) test woman child bear potential define postmenopausal 12 month previous surgical sterilization willing ongoing pregnancy test treatment lenalidomide . 10 . Woman child bear potential must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME . 11 . Men must agree use latex condom sexual contact female child bear potential even successful vasectomy . 12 . Laboratory test result within range : . Absolute neutrophil count &gt; 1000 cells/mm3 . b. Platelet count &gt; 50,000 cells/mm3 patient &lt; 50 % bone marrow plasma cell OR platelet count &gt; 25,000 cells/mm3 patient &gt; 50 % bone marrow nucleate cell plasma cell . c. Total bilirubin &lt; /= 2.0 mg/dL . d. AST ( SGOT ) ALT ( AGPT ) &lt; /= 3 x upper normal limit . 13 . Able take anticoagulation , warfarin equivalent agent , detail treatment plan . 14 . HIV negative . 1 . Any serious medical condition psychiatric illness would prevent subject signing informed consent form . 2 . Patients symptomatic relapse , include new bone lesion , soft tissue plasmacytoma , increase size exist bone lesion soft tissue plasmacytoma , decrease hemoglobin , rise serum creatinine hypercalcemia . 3 . Pregnant breast feeding female . ( Lactating female must agree breast feed take lenalidomide ) . 4 . Known hypersensitivity thalidomide lenalidomide . 5 . Known history resistance Thalidomide . 6 . Patients grade IIIIV neuropathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Blood And Marrow Transplantation</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>MM</keyword>
	<keyword>Autologous stem cell transplantation</keyword>
	<keyword>ASCT</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Thalomid</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Questionnaires</keyword>
	<keyword>Surveys</keyword>
</DOC>